Opus Point Partners Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Opus Point Partners Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$432K	Buy	12,005 +24	+0.2%	+$728	0.78%	33
2019 Q2	$320K	Hold	11,981	–	–	0.47%	51
2019 Q1	$322K	Sell	11,981 -2,918	-20%	-$68.1K	0.44%	56
2018 Q4	$241K	Sell	14,899 -5,929	-28%	-$115K	0.53%	32
2018 Q3	$432K	Buy	20,828 +5,500	+36%	+$86.5K	1.03%	28
2018 Q2	$234K	Sell	15,328 -21,405	-58%	-$382K	0.51%	45
2018 Q1	$825K	Buy	36,733 +29,853	+434%	+$827K	1.62%	23
2017 Q4	$207K	Sell	6,880 -8,759	-56%	-$280K	0.18%	60
2017 Q3	$589K	Buy	+15,639	New	+$509K	0.53%	44
2017 Q2	–	Sell	-11,130	Closed	-$383K	–	68
2017 Q1	$383K	Buy	11,130 +1,088	+11%	+$38.4K	0.28%	57
2016 Q4	$290K	Buy	+10,042	New	+$266K	0.23%	41

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Opus Point Partners Management's ACAD Position: Q3 2019 in Review

Opus Point Partners Management increased its Acadia Pharmaceuticals (ACAD) stake by 0.2% in Q3 2019, buying an estimated $728 and bringing the position to 12,005 shares worth $432K. The position accounts for 0.78% of the portfolio, ranked #33.

Opus Point Partners Management first reported a position in ACAD in Q4 2016 and has held it in 11 quarters since. The position peaked at $825K in Q1 2018. 231 funds tracked by Wall St. Rank hold ACAD as of Q3 2019.

Opus Point Partners Management held 12,005 shares of Acadia Pharmaceuticals worth $432K as of Q3 2019.
Opus Point Partners Management bought 24 Acadia Pharmaceuticals shares in Q3 2019, an estimated $728.
Acadia Pharmaceuticals made up 0.78% of Opus Point Partners Management's portfolio in Q3 2019, its #33 holding.
Opus Point Partners Management first reported a position in Acadia Pharmaceuticals in Q4 2016 and has held it in 11 quarters since.
Opus Point Partners Management's Acadia Pharmaceuticals position peaked at $825K in Q1 2018.
231 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.